Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $63.6 (market cap $79.86B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 81.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.32% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 108 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MDLZ | MRVI | |
|---|---|---|
Market Cap | $79.86B | $977.37M |
Volume | 7,299,804 | 2,742,564 |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $9.00 |
52-Week Low | $51.51 | $2.83 |
Typical Hold Time | 108 Days | 0 Days |
Enterprise Value | $100.20B | $1.08B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $61.50, down 0.47% on the day, with strong technical momentum indicated by bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth continues with $38.54 billion in 2025, though net income margin declined to 6.36% from 12.65% in 2024. Analyst consensus remains strongly bullish with a $70.29 price target, representing 14% upside potential.
MDLZ offers attractive valuation with a P/E of 22.53 and consistent dividend growth, recently raising its quarterly payout to $0.52. Key risks include cocoa cost pressures and margin compression, but the company's global brand strength and emerging market momentum provide stability. The stock presents a compelling opportunity for long-term investors seeking defensive exposure with dividend income.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
